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This study investigated the impact of bronchiectasis on patients admitted to the intensive care 
unit (ICU) at a hospital in Korea. Patients with bronchiectasis were diagnosed using results of chest 
computed tomography performed before ICU admission. The severity of bronchiectasis was based 
on the number of affected lobes, and patients with ≥ 3 bronchiectatic lobes were classified into the 
severe bronchiectasis group. Overall, 823 patients were enrolled. The mean age was 66.0 ± 13.9 years, 
and 63.4% were men. Bronchiectasis and severe bronchiectasis were present in 148 (18.0%) and 108 
(13.1%) patients, respectively. The increase in the number of bronchiectatic lobes was related to the 
rise in ICU mortality (P for trend = 0.012) and in‑hospital mortality (P for trend = 0.004). Patients with 
severe bronchiectasis had higher odds for 28‑day mortality [odds ratio (OR) 1.122, 95% confidence 
interval (CI) 1.024–1.230], ICU mortality (OR 1.119, 95% CI 1.023–1.223), and in‑hospital mortality (OR 
1.208, 95% CI 1.092–1.337). The severe bronchiectasis group showed lower overall survival (log‑rank 
P < 0.001), and the adjusted hazard ratio was 1.535 (95% CI 1.178–2.001). Severe bronchiectasis had a 
negative impact on all‑cause mortality during ICU and hospital stays, resulting in a lower survival rate.
Bronchiectasis is characterized by persistent dilatation of the  bronchi1. It impairs the clearance of bacteria and 
mucus from the airway, leading to progressive airway damage, decreased lung function, respiratory failure, and 
 death2. The true prevalence of bronchiectasis is unknown. It does seem to vary geographically, but there are 
many confounders to this: notably, access and ready use of computed tomography (CT), which is needed for 
 diagnosis3–5. Patients with bronchiectasis are known to have  multimorbidity6, experience frequent  exacerbation7, 
and present twofold increased mortality compared to the general  population4.
Although several studies have reported the impact of non-cystic fibrosis bronchiectasis (hereafter bronchiec-
tasis) on the general population, only a few studies have explored its impact on critically ill  patients8–10. Dupont 
et al.8 reviewed 48 bronchiectasis patients admitted in the medical intensive care unit (ICU) and found that 
age > 65 years and prior use of long-term oxygen therapy negatively affected the survival. Alzeer et al.9 presented 
similar results and found that age over 65 years, low physical activity, and the use of inotropic support were risk 
factors of mortality in bronchiectasis patients. A study from the UK reported worse mortality rates in the ICU 
and hospital among bronchiectasis patients than among patients with chronic obstructive pulmonary disease 
(COPD) in the elderly  population10.
However, the impact of bronchiectasis on critically ill patients is not fully understood, and, to the best of our 
knowledge, data from Korea have not been previously reported. Therefore, our study aimed to investigate the 
impact of bronchiectasis on patients admitted to the medical ICU at a tertiary referral hospital in Korea. The 
primary outcome was all-cause mortality assessed at 28 days after ICU admission, ICU mortality, and in-hospital 
mortality. The secondary outcomes were the durations of ICU and hospital stay and overall survival.
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Material and methods
Study design and population. This retrospective cohort study enrolled patients admitted to the 24-bed 
medical ICU of Severance Hospital, a tertiary referral hospital in Seoul, Korea, from July 1, 2016, to April 30, 
2019. The study was conducted according to the guidelines of the Declaration of Helsinki, and the study protocol 
was approved by the institutional review board of Severance Hospital (IRB No. 4-2020-1098). The committee 
waived the need for informed consent from the patients in consideration of the retrospective nature of the pre-
sent study.
According to our institutional policy, patients with acute coronary disease are admitted to a coronary care 
unit. Patients requiring immediate postoperative management are also admitted to the surgical ICU. Accord-
ingly, patients requiring mechanical ventilation or continuous renal replacement therapy were admitted to the 
medical ICU in the current study.
Patients who were aged > 18 years and underwent chest CT before ICU admission were considered eligible 
for this study. Patients without a chest CT scan taken prior to ICU admission or without an official CT report 
by thoracic radiologists were excluded.
Data collection and study outcome. The demographic data, laboratory findings, comorbidities, and 
hospital course were obtained from electronic medical records; these data included age, sex, body mass index 
(BMI), a history of COPD or asthma (from clinical diagnosis made by respiratory physicians, spirometry results, 
and prescription of inhalers), and the Charlson comorbidity index (CCI)11, Acute Physiology and Chronic Health 
Evaluation II (APACHE II)12, and Sequential Organ Failure Assessment (SOFA)  scores13. Mechanical ventila-
tory support and septic shock, based on the Third International Consensus definitions, were also  investigated14. 
Survival data were acquired until June 30, 2020.
Definition of bronchiectasis and radiologic severity. Bronchiectasis, including traction bronchiec-
tasis and bronchiolectasis, were detected using a chest CT scan before ICU admission. The radiological extent 
of bronchiectasis, evaluated by two independent pulmonary physicians, was used to represent disease severity 
according to the number of affected lobes; the presence of three or more bronchiectatic lobes out of a total of 
five lobes was considered to represent severe  bronchiectasis15–17. Patients with non-cystic fibrosis bronchiectasis 
were enrolled in this study because very few cases of infants with cystic fibrosis have been reported in Korea.
Statistical analyses. Categorical variables were analyzed using Pearson’s chi-squared test or Fisher’s exact 
test, and continuous variables were analyzed with Student’s t-test or the Mann–Whitney U test. The Cochran-
Armitage trend test was used for comparing changing trends. The odds ratio (OR) and 95% confidence interval 
(CI) for all-cause mortality were measured with logistic linear regression analysis. Survival analysis was also 
performed: overall survival with the Kaplan–Meier method and the statistical difference with the log-rank test. 
Hazard ratio (HR) and 95% CIs were evaluated with the Cox proportional-hazards model. All statistical analyses 
were conducted using the R program v4.0.2 (The R Foundation for Statistical Computing, Vienna, Austria), and 
a two-tailed P-value of < 0.05 was considered statistically significant.
Results
Baseline characteristics. Overall, 1207 patients were admitted to the ICU during the study period, and 
the eligibility screening identified 823 (68.2%) patients. The median interval between ICU admission and chest 
CT was 3 days (interquartile range: 0–24 days). The population’s baseline characteristics are presented in Table 1. 
There were 148 (18.0%) patients with bronchiectasis and 108 (13.1%) patients with severe bronchiectasis. There 
was no significant difference in the APACHE II score of the enrolled patients with or without severe bronchi-
ectasis. However, the initial SOFA score was lower in the group with severe bronchiectasis than in the group 
without (7.7 vs. 8.8, P = 0.009). In the severe bronchiectasis group, the lengths of ICU stay (13 days vs. 8 days, 
P < 0.001) and hospital stay (47 days vs. 35 days, P = 0.037) were longer and intubation rates (85.2% vs. 68.3%, 
P < 0.001) were higher.
We performed a subgroup analysis of patients with respiratory failure requiring intubation and mechanical 
ventilation (Table 2). The prevalence of bronchiectasis and severe bronchiectasis was 21.6% and 15.9%, respec-
tively. The initial SOFA score was also lower in the severe bronchiectasis group (7.9 vs. 9.0, P = 0.006), but the 
length of ICU and hospital stays was similar between the two groups.
Bronchiectasis and mortality. The crude 28-day mortality, ICU mortality, and in-hospital mortality rates 
were 28.7%, 26.1%, and 43.5%, respectively (Table 1). Patients with severe bronchiectasis had higher rates of 
ICU mortality (36.1% vs. 24.6%, P = 0.016) and in-hospital mortality (59.3% vs. 41.1%, P = 0.001) than did those 
without severe bronchiectasis. As more lobes were involved in bronchiectasis, higher rates of ICU mortality (P 
for trend = 0.012) and in-hospital mortality (P for trend = 0.004) were observed (Table 3).
In the subgroup analysis of intubated patients, the in-hospital mortality rate was higher for patients with 
severe bronchiectasis than for the other patients (62.0% vs. 48.2%, P = 0.021, Table 2), and the rate increased 
with an increase in the number of lobes involved in bronchiectasis (P = 0.043, Table 3).
After adjusting for age, sex, BMI, presence of COPD, APACHE II score, SOFA score, and CCI score, patients 
with severe bronchiectasis had higher odds of 28-day mortality (OR 1.122, 95% CI 1.024–1.230), ICU mortal-
ity (OR 1.119, 95% CI 1.023–1.223), and in-hospital mortality (OR 1.208, 95% CI 1.092–1.337) (Table 4). The 
severe bronchiectasis group among intubated patients also showed higher odds of in-hospital mortality (OR 
2.113, 95% CI 1.261–3.584).
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Table 1.  Baseline characteristics and outcomes of the study population. Note: Data are presented as numbers 
(%), mean ± standard deviation, or median [interquartile range]. APACHE II Acute Physiology and Chronic 
Health Evaluation II, BMI body mass index, CCI Charlson comorbidity index, COPD chronic obstructive 
pulmonary disease, CRRT continuous renal replacement therapy, ICU intensive care unit, SOFA sequential 
organ failure assessment.
Total (n = 823) Without severe Bronchiectasis (n = 715) Severe Bronchiectasis (n = 108) P-value
Age, years 66.0 ± 13.9 66.1 ± 14.1 65.1 ± 12.6 0.493
Sex, male 522 (63.4) 458 (64.1) 64 (59.3) 0.391
BMI, kg/m2 22.1 ± 4.4 22.4 ± 4.4 20.6 ± 3.8  < 0.001
APACHE II score 25.7 ± 9.0 25.6 ± 9.0 26.4 ± 9.1 0.439
SOFA score 8.6 ± 3.8 8.8 ± 3.8 7.7 ± 3.3 0.009
CCI score 3.7 ± 2.5 3.7 ± 2.5 3.5 ± 2.7 0.598
Asthma 52 (6.3) 40 (5.6) 12 (11.1) 0.047
COPD 99 (12.0) 71 (9.9) 28 (25.9)  < 0.001
Bronchiectasis 148 (18.0)
Severe bronchiectasis 108 (13.1)
Intubation 580 (70.5) 488 (68.3) 92 (85.2)  < 0.001
Septic shock 588 (71.4) 514 (71.9) 74 (68.5) 0.543
CRRT 294 (35.7) 266 (37.2) 28 (35.9) 0.030
Outcomes
28-day mortality 236 (28.7) 196 (27.4) 40 (37.0) 0.052
ICU mortality 215 (26.1) 176 (24.6) 39 (36.1) 0.016
In-hospital mortality 358 (43.5) 294 (41.1) 64 (59.3) 0.001
ICU stay, days 8 [4–17] 8 [4–17] 13 [6–22]  < 0.001
Hospital stay, days 36 [18–71] 35 [17–69] 47 [23–90] 0.037
Follow-up, months 2.6 [0.6–14.9] 2.8 [0.6–15.7] 2.0 [0.6–10.0] 0.109
Table 2.  Baseline characteristics and outcomes of intubated patients. Note: Data are presented as numbers (%), 
mean ± standard deviation, or median [interquartile range]. APACHE II Acute Physiology and Chronic Health 
Evaluation II, BMI body mass index, CCI Charlson comorbidity index, COPD chronic obstructive pulmonary 
disease, CRRT continuous renal replacement therapy, ICU intensive care unit, SOFA sequential organ failure 
assessment.
Total (n = 580) Without severe Bronchiectasis (n = 488) Severe Bronchiectasis (n = 92) P-value
Age, years 66.1 ± 13.9 66.4 ± 14.1 64.7 ± 13.0 0.267
Sex, male 383 (66.0) 328 (67.2) 55 (59.8) 0.208
BMI, kg/m2 22.0 ± 4.4 22.2 ± 4.5 20.7 ± 3.7 0.001
APACHE II score 27.6 ± 8.6 27.8 ± 8.6 26.8 ± 9.1 0.321
SOFA score 8.8 ± 3.9 9.0 ± 4.0 7.9 ± 3.2 0.006
CCI score 3.6 ± 2.5 3.6 ± 2.5 3.5 ± 2.7 0.666
Asthma 45 (7.1) 35 (7.2) 10 (10.9) 0.316
COPD 83 (14.3) 56 (11.5) 27 (29.3)  < 0.001
Bronchiectasis 125 (21.6)
Severe bronchiectasis 92 (15.9)
Septic shock 435 (75.0) 367 (75.2) 68 (73.9) 0.896
CRRT 179 (30.9) 156 (32.0) 23 (25.0) 0.229
Outcomes
28-day mortality 192 (33.1) 157 (32.2) 35 (38.0) 0.329
ICU mortality 190 (32.8) 153 (31.4) 37 (40.2) 0.123
In-hospital mortality 292 (50.3) 235 (48.2) 57 (62.0) 0.021
ICU stay, day 12 [6–21] 11 [6–21] 14 [8–24] 0.056
Hospital stay, day 40 [20–74] 40 [20–72] 50 [25–108] 0.055
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Survival analysis. The severe bronchiectasis group showed a lower overall survival rate than did the other 
group (Log-rank P < 0.001, Fig. 1), and the adjusted HR from the Cox proportional-hazards model was 1.535 
(95% CI 1.178–2.001). Among the intubated patients, the overall survival of the severe bronchiectasis group 
was similar to that of the control group (Log-rank P = 0.099, Fig. 2), but the adjusted HR was 1.434 (95% CI 
1.069–1.922) in the Cox proportional-hazards model.
Discussion
In our study, the prevalence of bronchiectasis and its impact on critically ill patients were presented. The crude 
prevalence rates were 18.0% for bronchiectasis and 13.1% for severe bronchiectasis among those admitted to 
the medical ICU. Patients with severe bronchiectasis required prolonged ICU and hospital stays; moreover, 
severe bronchiectasis was a risk factor of all-cause death during ICU and in-hospital admission, thus lowering 
the survival rate.
Bronchiectasis is a common respiratory condition. The prevalence of bronchiectasis differs geographically: 
(per 100,000 individuals) 67–566 cases in  Europe4, 18, 19, 139 cases (age > 18 years) and 1,106 cases (age ≥ 65 years) 
in the  US3, 20, and > 1,200 cases (age > 40 years) in  China21. The variations in the prevalence estimates might be 
due to host factor susceptibilities, etiologic differences, and analyzed data  sets22. However, in recent decades, the 
prevalence and incidence of bronchiectasis have increased in an age-dependent  manner3, 4, 18–21.
Limited data were available on bronchiectasis among patients admitted in the ICU. Navaratnam et al.10 
reported that 536 patients (0.1%) among 614,352 patients were admitted to 219 critical care units because of 
bronchiectasis from 2009 to 2013 in the UK. The number of ICU admissions owing to bronchiectasis increased 
annually by 8% (95% CI 2–15), while those due to COPD increased by 1% (95% CI 0.3–2). In our study, there 
Table 3.  Number of bronchiectatic lobes and mortality. Note: Data are presented as numbers (%). ICU 
intensive care unit.
No. of Bronchiectatic Lobes
0 1 2 3 4 5 P for trend
All patients (n = 823) (n = 675) (n = 16) (n = 24) (n = 22) (n = 24) (n = 62)
28-day mortality 187 (77.7) 5 (31.2) 4 (16.7) 7 (31.8) 8 (33.3) 25 (40.3) 0.058
ICU mortality 169 (25.0) 3 (18.8) 4 (16.7) 5 (22.7) 8 (33.3) 26 (41.9) 0.012
In-hospital mortality 284 (42.1) 5 (31.2) 5 (20.8) 9 (40.9) 17 (70.8) 38 (61.3) 0.004
Intubated patients (n = 580) (n = 455) (n = 15) (n = 18) (n = 19) (n = 18) (n = 55)
28-day mortality 148 (32.5) 5 (33.3) 4 (22.2) 7 (36.8) 5 (27.8) 23 (41.8) 0.323
ICU mortality 146 (32.1) 3 (20.0) 4 (22.2) 5 (26.3) 6 (33.3) 26 (47.3) 0.095
In-hospital mortality 225 (49.5) 5 (33.3) 5 (27.8) 9 (47.4) 13 (72.2) 35 (63.6) 0.043
Table 4.  Logistic regression analysis for all-cause mortality. APACHE II Acute Physiology and Chronic Health 
Evaluation II, BMI body mass index, CCI Charlson comorbidity index, CI confidence interval, OR odds ratio.
28-day mortality ICU mortality In-hospital mortality
Adjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
All patients (n = 758)
Age, year 1.000 (0.998–1.002) 0.908 0.999 (0.997–1.001) 0.318 1.000 (0.998–1.003) 0.890
Sex, female 1.018 (0.955–1.084) 0.586 1.021 (0.961–1.086) 0.499 1.007 (0.939–1.080) 0.838
BMI, kg/m2 1.005 (0.997–1.011) 0.209 1.001 (0.994–1.008) 0.790 1.003 (0.995–1.010) 0.518
COPD 1.020 (0.925–1.124) 0.697 0.974 (0.886–1.071) 0.593 1.012 (0.909–1.127) 0.829
APACHE II score 1.010 (1.006–1.013)  < 0.001 1.008 (1.004–1.011)  < 0.001 1.010 (1.006–1.014)  < 0.001
SOFA score 1.030 (1.020–1.039)  < 0.001 1.031 (1.022–1.040)  < 0.001 1.027 (1.017–1.037)  < 0.001
CCI score 1.009 (0.997–1.021) 0.129 1.008 (0.997–1.020) 0.158 1.017 (1.003–1.030) 0.015
Severe bronchiectasis 1.122 (1.024–1.230) 0.014 1.119 (1.023–1.223) 0.014 1.208 (1.092–1.337)  < 0.001
Intubated patients (n = 539)
Age, year 1.000 (0.998–1.003) 0.869 0.996 (0.982–1.010) 0.570 1.006 (0.992–1.019) 0.412
Sex, female 1.043 (0.965–1.128) 0.290 1.266 (0.834–1.919) 0.267 1.132 (0.768–1.672) 0.532
BMI, kg/m2 1.004 (0.995–1.012) 0.419 1.005 (0.960–1.051) 0.845 1.008 (0.966–1.052) 0.718
COPD 1.020 (0.914–1.139) 0.724 0.944 (0.523–1.746) 0.851 1.109 (0.639–1.939) 0.713
APACHE II score 1.007 (1.003–1.012) 0.003 1.023 (0.998–1.049) 0.072 1.020 (0.997–1.045) 0.095
SOFA score 1.041 (1.029–1.052)  < 0.001 1.206 (1.137–1.282)  < 0.001 1.188 (1.124–1.259)  < 0.001
CCI score 1.009 (0.994–1.023) 0.255 1.047 (0.969–1.131) 0.240 1.071 (0.995–1.153) 0.067
Severe bronchiectasis 1.098 (0.990–1.219) 0.078 1.726 (0.999–2.960) 0.048 2.113 (1.261–3.584) 0.005
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were 18.0% and 13.1% of the patients with bronchiectasis and severe bronchiectasis, respectively, among the ICU-
admitted patients. The high prevalence of bronchiectasis and severe bronchiectasis in our study might result from 
the high rate of respiratory failure and intubation. Since our study was conducted in the non-coronary medical 
ICU, frequent chest CT scans to evaluate thoracic lesions might have led to a high prevalence of bronchiectasis 
and severe bronchiectasis. In addition, Yang et al. reported from a national database study that lower family 
income and comorbid pulmonary conditions such as previous pulmonary tuberculosis were independently 
associated with bronchiectasis in  Korea23. As Korea was one of the fastest developing countries in the late 1900s 
and still has an intermediate burden of  tuberculosis24, these factors might have contributed to the high prevalence 
of bronchiectasis in this study.
Bronchiectasis patients usually have multiple comorbidities. A European international cohort study 
revealed that bronchiectasis patients had a median of four diseases (interquartile range 2–6, range 0–20), which 
Figure 1.  Survival analysis of the study group. (a) Kaplan–Meier curve and Log-rank test. (b) HRs of significant 
variables. Age, sex, BMI, and COPD were adjusted. Asterisks represent P-values: * < 0.05, ** < 0.01, *** < 0.001. 
APACHE-II Acute Physiology and Chronic Health Evaluation II, BMI body mass index, CCI Charlson 
comorbidity index, CI confidence interval, COPD chronic obstructive pulmonary disease, HR hazard ratio, 
SOFA sequential organ failure assessment.
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significantly contributed to disease burden and  mortality6. In our study, bronchiectasis also seemed to contribute 
to chronic medical conditions. The ICU mortality and in-hospital mortality were higher in patients with severe 
bronchiectasis, whereas 28-day mortality, a possible surrogate marker of acute stage severity, showed no dif-
ference between the two groups. Also, 28-day mortality and ICU mortality among the intubated patients were 
similar between those with and without severe bronchiectasis. In contrast, the duration of ICU and in-hospital 
stays were longer in patients with severe bronchiectasis regardless of intubation. Although initial comorbidities 
represented by CCI scores were similar between the two groups, severe bronchiectasis might have contributed 
to the underlying medical condition and provoked complications during the admission.
Figure 2.  Survival analysis among the intubated patients. (a) Kaplan–Meier curve and Log-rank test. (b) HRs 
of significant variables. Age, sex, BMI, and COPD were adjusted. Asterisks represent P-values: * < 0.05, ** < 0.01, 
*** < 0.001. APACHE-II Acute Physiology and Chronic Health Evaluation II, BMI body mass index, CCI 
Charlson comorbidity index, CI confidence interval, COPD chronic obstructive pulmonary disease, HR hazard 
ratio, SOFA sequential organ failure assessment.
7
Vol.:(0123456789)
Scientific Reports |        (2021) 11:15757  | https://doi.org/10.1038/s41598-021-95366-z
www.nature.com/scientificreports/
Prolonged ICU stay accelerates ICU-acquired weakness and increases health-related  costs25. Moreover, bron-
chiectasis results in economic and psychological burdens, not only among patients, but also among  caregivers26–28. 
ICU stays impose higher medical expenditures than those in general  wards29, 30. In our study, we could not 
directly measure medical expenses; however, the duration of ICU and hospital stay were longer in the severe 
bronchiectasis group.
The strength of our study is that we simplified the severity of bronchiectasis as the number of affected lobes 
on chest CT scans and measured the impact of severe bronchiectasis on overall mortality. Several studies used 
the Bronchiectasis Severity  Index16 or FACED  score17 to grade disease severity. Both scores require spirometry 
results, dyspnea scale of the Medical Research Council, sputum culture for bacterial colonization, and chest CT 
scans. However, only the radiological extent of bronchiectasis was used in our study for evaluating the severity 
since critically ill patients often lack prior pulmonary function tests in actual practice. Additionally, incidental 
diagnosis of bronchiectasis on chest CT scans was common; therefore, we decided to use the radiological extent 
to reflect the severity in the ICU setting. We found that the radiological severity of three or more bronchiectatic 
lobes indicated a clinically useful predictor of all-cause mortality among critically ill patients.
Our study is subject to limitations. First, this was a single-center retrospective study. A prospective multi-
center study is needed for confirming the impact of bronchiectasis on critically ill patients. Second, there may 
be selection bias as chest CT scans were acquired for 68.2% of all ICU-admitted patients. Third, the relation-
ship between the number of bronchiectatic lobes and mortality could not be established. Since patients with 
bronchiectasis accounted for 18.0% of the study population, dividing them by the number of lobes resulted in 
insufficient numbers in each subgroup. Thus, further studies with a larger population would be required. Fourth, 
the impact of bronchiectasis on the specific cause of death could not be evaluated. Sin et al.31 reported that the 
increased risk of all-cause mortality in bronchiectasis patients was related to respiratory disease and lung cancer 
when compared with the control population in Korea. However, as ICU-admitted patients usually have multiple 
organ damage, it is hard to define the specific reason for mortality. Additionally, bronchiectasis might be an 
indirect cause of death. In our study, intubated patients with severe bronchiectasis showed an extended dura-
tion of ICU and hospital stays and higher in-hospital mortality despite the lower initial SOFA score. Therefore, 
severe bronchiectasis might be associated with a risk of all-cause death other than respiratory-related mortality. 
Fifth, we could not compare patients with bronchiectasis to patients with other respiratory diseases, because of 
the small number of patients with bronchiectasis exacerbation enrolled in this study. Sixth, the review of res-
piratory symptoms or prior colonization patterns of high-risk organisms was limited due to the retrospective 
design and the study setting, a tertiary referral center. Lastly, we did not specify the ICU admission diagnosis 
and only performed subgroup analysis in patients with respiratory failure requiring mechanical ventilation. 
Thus, exacerbation of bronchiectasis or superimposed pneumonia in sections of the study population might 
have confounded the results.
In conclusion, the prevalence of non-cystic fibrosis bronchiectasis was common in an ICU of a tertiary 
hospital in Korea. Severe bronchiectasis could be a risk factor for all-cause mortality during ICU and hospital 
stays, lowering the survival rate. The radiological extent of bronchiectasis could be a clinical predictor of poor 
prognosis. Since there are no clinical guidelines to manage patients with bronchiectasis in the ICU, further study 
would be needed.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
Received: 17 March 2021; Accepted: 26 July 2021
References
 1. Chalmers, J. D., Chang, A. B., Chotirmall, S. H., Dhar, R. & McShane, P. J. Bronchiectasis..  Nat. Rev. Dis. Primers 4, 45 (2018).
 2. McShane, P. J., Naureckas, E. T., Tino, G. & Strek, M. E. Non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 188, 
647–656 (2013).
 3. Seitz, A. E., Olivier, K. N., Adjemian, J., Holland, S. M. & Prevots, D. R. Trends in bronchiectasis among medicare beneficiaries in 
the United States, 2000 to 2007. Chest 142, 432–439 (2012).
 4. Quint, J. K. et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: A population-
based cohort study. Eur. Respir. J. 47, 186–193 (2016).
 5. Hess, E. P. et al. Trends in computed tomography utilization rates: A longitudinal practice-based study. J. Patient Saf. 10, 52–58 
(2014).
 6. McDonnell, M. J. et al. Comorbidities and the risk of mortality in patients with bronchiectasis: An international multicentre cohort 
study. Lancet Respir. Med. 4, 969–979 (2016).
 7. Chalmers, J. D. et al. Characterization of the “frequent exacerbator phenotype” in bronchiectasis. Am. J. Respir. Crit. Care Med. 
197, 1410–1420 (2018).
 8. Dupont, M. et al. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. Chest 125, 1815–1820 
(2004).
 9. Alzeer, A. H., Masood, M., Basha, S. J. & Shaik, S. A. Survival of bronchiectatic patients with respiratory failure in ICU. BMC Pulm. 
Med. 7, 17 (2007).
 10. Navaratnam, V., Muirhead, C. R., Hubbard, R. B. & De Soyza, A. Critical care admission trends and outcomes in individuals with 
bronchiectasis in the UK. QJM 109, 523–526 (2016).
 11. Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal 
studies: Development and validation. J. Chronic Dis. 40, 373–383 (1987).
 12. Knaus, W. A., Draper, E. A., Wagner, D. P. & Zimmerman, J. E. APACHE II: A severity of disease classification system. Crit. Care 
Med. 13, 818–829 (1985).
8
Vol:.(1234567890)
Scientific Reports |        (2021) 11:15757  | https://doi.org/10.1038/s41598-021-95366-z
www.nature.com/scientificreports/
 13. Vincent, J. L. et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf 
of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22, 
707–710 (1996).
 14. Singer, M. et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315, 801–810 (2016).
 15. Crisafulli, E. et al. Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive 
pulmonary disease: A propensity matched analysis. Sci. Rep. 8, 9236 (2018).
 16. Chalmers, J. D. et al. The bronchiectasis severity index. An international derivation and validation study. Am. J. Respir. Crit. Care 
Med. 189, 576–585 (2014).
 17. Martínez-García, M. et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: The FACED score. Eur. Respir. J. 43, 
1357–1367 (2014).
 18. Ringshausen, F. C. et al. Bronchiectasis in Germany: A population-based estimation of disease prevalence. Eur. Respir. J. 46, 
1805–1807 (2015).
 19. Sánchez-Muñoz, G. et al. Time trends in hospital admissions for bronchiectasis: Analysis of the Spanish National Hospital Dis-
charge Data (2004 to 2013). PLoS ONE 11, e0162282 (2016).
 20. Weycker, D., Hansen, G. L. & Seifer, F. D. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. 
Chron. Respir. Dis. 14, 377–384 (2017).
 21. Lin, J. L., Xu, J. F. & Qu, J. M. Bronchiectasis in China. Ann. Am. Thorac. Soc. 13, 609–616 (2016).
 22. Chandrasekaran, R., Mac Aogáin, M., Chalmers, J. D., Elborn, S. J. & Chotirmall, S. H. Geographic variation in the aetiology, 
epidemiology and microbiology of bronchiectasis. BMC Pulm. Med. 18, 83 (2018).
 23. Yang, B. et al. Factors associated with bronchiectasis in Korea: A national database study. Ann. Transl. Med. 8, 1350 (2020).
 24. Global tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO
 25. Vanhorebeek, I., Latronico, N. & Van den Berghe, G. ICU-acquired weakness. Intensive Care Med. 46, 637–653 (2020).
 26. Joish, V. N., Spilsbury-Cantalupo, M., Operschall, E., Luong, B. & Boklage, S. Economic burden of non-cystic fibrosis bronchiectasis 
in the first year after diagnosis from a US health plan perspective. Appl. Health Econ. Health Policy 11, 299–304 (2013).
 27. O’Leary, C. J. et al. Relationship between psychological well-being and lung health status in patients with bronchiectasis. Respir. 
Med. 96, 686–692 (2002).
 28. Kapur, N., Masters, I. B., Newcombe, P. & Chang, A. B. The burden of disease in pediatric non-cystic fibrosis bronchiectasis. Chest 
141, 1018–1024 (2012).
 29. Curtis, J. R., Engelberg, R. A., Bensink, M. E. & Ramsey, S. D. End-of-life care in the intensive care unit: Can we simultaneously 
increase quality and reduce costs?. Am. J. Respir. Crit. Care Med. 186, 587–592 (2012).
 30. Lerolle, N. et al. Increased intensity of treatment and decreased mortality in elderly patients in an intensive care unit over a decade. 
Crit. Care Med. 38, 59–64 (2010).
 31. Sin, S. et al. Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis. Respir. Res. 20, 271 (2019).
Acknowledgements
This work was supported by the Korea Medical Device Development Fund grant funded by the Korean govern-
ment (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & 
Welfare, the Ministry of Food and Drug Safety) (Project Number: 202011B26).
Author contributions
SHL designed and supervised the study. YP and SHL acquired the data. All authors analyzed the results. YP wrote 
the draft of main manuscript. All authors reviewed and approved final manuscript.
Competing interests 
The authors declare no competing interests.
Additional information
Correspondence and requests for materials should be addressed to S.H.L.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
© The Author(s) 2021
